⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29562566 | 1.00 | — | — | |
| SCHEMBL11808156 | 0.79 | — | — | |
| SCHEMBL28628599 | 0.79 | — | — | |
| SCHEMBL30398249 | 0.79 | — | — | |
| SCHEMBL2596902 | 0.75 | — | — | |
| SCHEMBL6172813 | 0.75 | — | — | |
| SCHEMBL16051380 | 0.75 | — | — | |
| SCHEMBL18338657 | 0.75 | — | — | |
| SCHEMBL22465644 | 0.75 | — | — | |
| SCHEMBL1516762 | 0.75 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 123 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115894353-A | Synthetic method of 2, 3-diamino-4-bromopyridine | 山西永津集团有限公司 | 2023-04-04 | — | — | CN | claimed |
| US-20260035367-A1 | PKC-Theta Modulators | CELGENE CORPORATION (US) | 2026-02-05 | — | — | US | disclosed |
| EP-4634170-A1 | IMIDAZO[4,5-B]PYRIDINE DERIVATIVES AS PCSK9 INHIBITORS AND METHODS OF USE THEREOF | AstraZeneca AB (SE) | 2025-10-22 | — | — | EP | disclosed |
| US-12415803-B2 | Fused imidazopyridines as reversible inhibitors of Brutons Tyrosine Kinase (BTK) | MERCK PATENT GMBH (DE) | 2025-09-16 | — | — | US | disclosed |
| US-20250066349-A1 | CYCLIC COMPOUNDS AND THEIR USE FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | PROTHENA BIOSCIENCES LIMITED (IE) | 2025-02-27 | — | — | US | disclosed |
| EP-4444420-A2 | CYCLIC COMPOUNDS AND THEIR USE FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | Prothena Biosciences Limited (IE) | 2024-10-16 | — | — | EP | disclosed |
| US-20240262821-A1 | PKC-Theta Modulators | EXSCIENTIA AL LIMITED (GB) | 2024-08-08 | — | — | US | disclosed |
| US-20240239794-A1 | PKC-Theta Modulators | EXSCIENTIA AI LIMITED (GB) | 2024-07-18 | — | — | US | disclosed |
| US-20240239794-A1 | PKC-Theta Modulators | EXSCIENTIA AI LIMITED (GB) | 2024-07-18 | — | — | US | disclosed |
| US-20240239767-A1 | PCSK9 INHIBITORS AND METHODS OF USE THEREOF | ASTRAZENECA AB (SE) | 2024-07-18 | — | — | US | disclosed |
| US-20160096834-A1 | HETEROARYL COMPOUNDS AS BTK INHIBITORS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2016-04-07 | — | — | US | disclosed |
| US-20160096834-A1 | HETEROARYL COMPOUNDS AS BTK INHIBITORS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2016-04-07 | — | — | US | disclosed |
| WO-2015187684-A1 | TANK-BINDING KINASE INHIBITOR COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2015-12-10 | — | — | WO | disclosed |
| WO-2015187684-A1 | TANK-BINDING KINASE INHIBITOR COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2015-12-10 | — | — | WO | disclosed |
| US-20150344473-A1 | TANK-BINDING KINASE INHIBITOR COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2015-12-03 | — | — | US | disclosed |
| US-20150344473-A1 | TANK-BINDING KINASE INHIBITOR COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2015-12-03 | — | — | US | disclosed |
| US-20150344473-A1 | TANK-BINDING KINASE INHIBITOR COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2015-12-03 | — | — | US | disclosed |
| WO-2014106763-A1 | PYRIDOPYRAZINES AS ANTICANCER AGENTS | VICHEM CHEMIE KUTATÓ KFT. (HU) | 2014-07-10 | — | — | WO | disclosed |
| CN-103435561-A | Novel D-amino acid oxidase inhibitor and preparation and application thereof | UNIV SHANGHAI JIAOTONG | 2013-12-11 | — | — | CN | disclosed |
| US-20040180947-A1 | hypoglycemic activity or phoshodiesterase-V inhibitory activity; prophylaxis and treatment of impaired glucose tolerance disorder, diabetes (e.g., type II diabetes), diabetic complications | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-09-16 | — | — | US | disclosed |